Annual Meeting Clinical Trials Plenary Session, Sanofi presented data on tolebrutinib in patients with non-relapsing ...

Higher doses of the company’s intravenously delivered multiple sclerosis drug failed to show additional benefit in slowing ...

Annexon (ANNX) presented data for its late-stage targeted therapy for GBS and showcased new disease education activities at the AAN Annual ...

Annexon's tanruprubart showed significant and sustained functional gains in Guillain-Barré patients, meeting key Phase 3 ...

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosisResults from the HERCULES phase 3 ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, ...

Administration of low-dose valacyclovir over a year does not significantly reduce the occurrence of herpes zoster ...

Zenas BioPharma, Inc.'s obexelimab's potential in treating autoimmune diseases and upcoming phase 2 & 3 trial results. Read ...

In the European Union and the United Kingdom, aflibercept 8mg (Eylea HD in the US) is currently approved for neovascular ...

Roche said a trial for its multiple-sclerosis drug Ocrevus failed to meet its primary endpoint in showing additional benefit in slowing disability progression with a higher dose. The Swiss ...

failed to meet its primary endpoint. The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression using a ...